We have recently demonstrated that the 1CF11 monoclonal antibody bound human milk lactoferrin (hLf) through the recognition of two distinct portions of the molecule, namely the N-glycan-relevant and -irrelevant structural elements. In this present study, we prepared four immunoreactive peptide fractions containing N-linked glycan from tryptic digests of reduced and alkylated hLf by using a concanavalin A lectin column and reverse-phase HPLC. Deglycosylation of these fractions and a competitive binding assay using fucosylated oligosaccharides revealed that the nonreducing terminal fucose residue in N-linked glycan(s) played a significant role in recognizing the N-glycanrelevant element in hLf by 1CF11.
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Key words: 1CF11; epitope; human milk lactoferrin; fucose; N-linked glycan Human milk lactoferrin (hLf) consists of a single polypeptide chain of 692 residues 1) and is folded into two globular lobes (N-lobe, residues 1-333; C-lobe, residues 345-692) that contain one metal-binding site per lobe.
2)
The protein possesses three possible N-glycosylation sites located at the asparagine residue (Asn 138 , Asn 479 , and Asn 624 ), and these sites are normally substituted by a complex type of N-glycan, except the third site (Asn 624 ) which is mostly unglycosylated.
3) It is also known that hLf has many physiological functions such as antimicrobial and anti-inflammatory activities. Many of these functions are mediated by such ability as sequestration of the free iron ion, 4) binding of the N-terminal cationic portion to bacterial lipopolysaccharide 5) and inhibition of the production of hydroxyl radicals, 6) whereas the role of glycosylation of the molecule in these functions is mostly unclear.
We have already reported that a monoclonal antibody (mouse IgM referred to as 1CF11) raised against purified human milk MUC1 mucin might specifically recognize a certain unique carbohydrate epitope shared by glycoproteins in human external secretions. [7] [8] [9] We have recently revealed that both hLf and its tryptic digests, after being deglycosylated with N-glycosidase F, showed a significant reduction in their immunoreactivity, although the reaction was never lost. 10) This result clearly indicated that hLf carried two distinct structural elements, the N-glycan-relevant and the N-glycanirrelevant portions, that were recognized by 1CF11 in the molecule. Elucidation of their precise chemical requirements may allow us to fully comprehend the significance of glycosylation in the protein.
We focused this present study on the structure of the N-glycanrelevant reactive portion of hLf, and consequently reveal that a fucose (Fuc) residue linked to an external N-acetylglucosamine (GlcNAc) residue in N-linked glycan(s) played a significant role in the recognition of the N-glycan-relevant structural element in hLf by 1CF11. We additionally describe a glycan-relevant epitope structure preferably recognized by 1CF11. Peptides carrying N-linked glycan were prepared from tryptic digests of reduced and carboxymethylated hLf, before chromatographic separation in a column filled with ConA Sepharose 4B (GE Healthcare, Buckinghamshire, UK). The ConA lectin-bound fraction (ConA BO) containing peptides with N-linked glycan were further separated into six fractions by reversephase HPLC on Cosmosil 5C18 AR-II (Nacalai Tesque, Kyoto, Japan), as shown in Fig. 1A . An aliquot of each fraction was then dried by centrifugation under vacuum, dissolved in 50 mM ammonium bicarbonate at pH 8.0, the N-glycosidase F enzyme (Roche, Mannheim, Germany) was added at 4 U/mg of the substrate, and the mixture incubated at 37 C for 20 h. The immunoreactivity with 1CF11 of each fraction was examined by dot blotting with and without deglycosylation. The peptides in the fractions were immobilized on a PVDF membrane, probed with 1CF11 and then by the HRPconjugated goat anti-mouse IgM antibody (American Qualex, San Clemente, USA), detecting the reaction by a chemiluminescence reagent (Immobilon Western, Millipore, Billerica, USA). As shown in Fig. 1B , unambiguous reactivity with 1CF11 was observed in each of the four later-eluted fractions (F16-17, F18, F19 and F20), whereas hardly any reactivity could be observed in the two earlier-eluted fractions (F11 and F13-15). Furthermore, the reactivity of the former four reactive fractions was almost entirely abolished after deglycosylation by using N-glycosidase F (Fig. 1B) , indicating that there were two N-linked glycans in hLf, In order to identify the structural feature within the 1CF11-reactive N-linked glycan of hLf that conferred recognition by 1CF11, the four 1CF11-reactive fractions were subjected to sequential exoglycosidase digestion or an endoglycosidase F2 treatment. Sequential exoglycosidase digestion was carried out on an aliquot of each fraction that was initially dried by centrifugation under vacuum and dissolved in a 50 mM ammonium acetate buffer at pH 5.5, before adding neuraminidase (4 mU/mg, from Arthrobactor ureafaciens; Roche, Mannheim, Germany). After incubating at 37 C for 24 h, each reaction mixture was boiled for 5 min to terminate the desialylation. An aliquot was then removed from each of the reaction mixtures, and 1,3/4 fucosidase (5 mU/mg, from Streptomyces sp. 142, Takara Biotechnology, Otsu, Japan) and 1,4 galactosidase (3 mU/mg, from Streptococcus pneumoniae, SigmaAldrich, St. Louis, MO, USA) were sequentially added. Deglycosylation with each of the two exoglycosidases was carried out in the same manner as that described for the neuraminidase treatment. A final treatment with endoglycosidase F2 (from Elizabethkingia meningosepticum, Sigma-Aldrich, St. Louis, MO, USA) was performed according to the manufacturer's instructions. The immunoreactivity after the deglycosylation with each glycosidase was examined by dot blotting in the same way as that already shown for N-glycosidase F. Removal of the targeted sugar constituent from the peptides in each digestion step was verified by MALDI-TOF MS spectroscopy (data not shown).
As shown in Fig. 1Cb , the reactivity for 1CF11 to the four 1CF11-reactive fractions was hardly influenced by the treatment with neuraminidase, but was significantly diminished by the subsequent treatment with 1,3/4 fucosidase (Fig. 1Cc) . The reactivity of the F16-17 fraction was almost completely abolished, while partial reactivity remained for the other three fractions (F18, F19, and F20) after deglycosylation with 1,3/4 fucosidase. Further treatment with 1,4 galactosidase left the reactivity almost unchanged (Fig. 1Cd) .
It has been reported that hLf bears biantennarybranched glycans of the N-acetyl-lactosamine and/or N-acetyl-polylactosamine type with/without sialylation. One of the typical features of these glycans is that most carry a Fuc residue linked 1,6 to an innermost GlcNAc residue and/or 1,3 to an external GlcNAc residue. [11] [12] [13] Since 1,3/4 fucosidase specifically cleaves the 1,3-or 1,4-fucoside bond, the significant reduction in reactivity of the four fractions appears to be attributable to the cleavage of an 1,3-linked Fuc residue. In a similar context, endoglycosidase F2 cleaves the glycosidic bond between two GlcNAc residues in the diacetylchitobiose core of the N-linked glycan, generating a glycopeptide containing one GlcNAc residue with/without an 1,6-linked Fuc residue. Since no reaction with 1CF11 was apparent in the glycopeptide obtained by this endoglycosidase treatment (Fig. 1Ce) , it could be concluded that the Fuc residue linked 1,6 to the innermost GlcNAc residue, if present, did not contribute to the recognition of the N-linked glycan of hLf by 1CF11.
Taken together, these results strongly indicate that a certain oligosaccharide portion containing an 1,3-linked Fuc residue at the non-reducing end played a key role in the recognition of the 1CF11-reactive N-linked glycan(s) in hLf by 1CF11. Additionally, some truncated N-linked glycans by treating with exoglycosidases would include a part of the reactive portion for 1CF11 (Fig. 1Cd) . Since no reaction was apparent in peptides or glycopeptides obtained by treating with either N-glycosidase F (Fig. 1B) or endoglycosidase F2 (Fig. 1Ce) , the N-glycan-irrelevant structural element seemed not to exist in ConA BO.
A possible trisaccharide (Gal1-4[Fuc1-3]GlcNAc) at the non-reducing end of N-linked glycan(s) on hLf is known as the Lewis x blood group antigen, [11] [12] [13] so that Le x might be one candidate for the 1CF11 epitope. The immunoreactivity of 1CF11 to several fucosylated oligosaccharides containing Le x was then examined by a competitive binding assay to verify the recognition of a glycan-relevant epitope structure by 1CF11. The sugar sequence and suppliers of the oligosaccharides as competitors are summarized in Table 1 . A microtiter plate was coated with 200 ng of hLf in 100 ml of 50 mM sodium carbonate at pH 9.6, incubated overnight at 4 C and washed three times with PBST. After the wells had been blocked with 1% BSA in PBS at 37
C for 1 h and washed in the same way, 100 ml of a competitor oligosaccharide, which had been premixed with an equal part of 1:7,500-diluted 1CF11 in PBS and preincubated at 37 C for 1 h, was added to each well, and the plate incubated at 37 C for 1 h. The amount of the antibody bound to immobilized hLf was detected by using the 1:15,000-diluted HRP-conjugated goat antimouse IgM antibody and o-phenylenediamine, before measuring the absorbance at 492 nm. The net specific binding of the antibody in the presence of the competitor was determined by subtracting the nonspecific binding determined for the uncoated wells without hLf and compared to the total net specific binding to hLf in the absence of the competitor (100%). Assays were performed in triplicate.
As shown in Fig. 2 , the weakest inhibition of 1CF11 binding to hLf was observed for Le x among the oligosaccharides tested, whereas LNFP II was more potent in its inhibition. When Le a and Le b (both containing an 1,4-linked Fuc) were compared, a marked reduction in inhibition was observed for Le b by an additional Fuc residue linked 1,2 to the terminal galactose (Gal) residue. The inhibitory activity of all Lewis-type antigens was also increased by elongating with lactose linked 1,3 at the reducing end (LNFP II, LNDFH I, and LNFP III), although no reactivity for 1CF11 to lactose was apparent (data not shown). These results as a whole suggest that 1CF11 recognized an oligosaccharide containing a Fuc residue, intrinsically preferred 1,4-linked to a type I core sequence (Gal1-3GlcNAc) than 1,3-linked to a type II (Gal1- 4GlcNAc), and was reluctant to act to an additional Fuc 1,2-linked to a Gal residue. It also required an antigen sequence elongation, for example with lactose (Gal1-4Glc), to enhance the recognition.
It seems unreasonable that the reactivity of 1CF11 to hLf carrying poorly reactive Le x was higher than that of more reactive antigens such as Le a and LNFP II (Fig. 2) . Two distinct reactive portions in hLf, the N-glycanrelevant and the N-glycan-irrelevant, probably possessed almost equal reactivity to 1CF11, because the reactivity of both hLf and its tryptic digests remained at about half the level after being deglycosylated with N-glycosidase F (data not shown). It is predicted that the higher reactivity of hLf would have been responsible for the enhanced avidity due to multivalent binding of 1CF11, a decavalent monoclonal antibody, to both the N-glycanrelevant and N-glycan-irrelevant reactive portions.
In conclusion, we have demonstrated that the nonreducing terminal fucose residue in N-linked glycans played a significant role in the recognition by 1CF11 of the N-glycan-relevant structural element in hLf. The multivalent interaction between 1CF11 and the two distinct structural elements in hLf would have been greatly involved in the recognition of the whole molecule of hLf by this antibody. The overall structure of reactive N-linked glycans or the N-glycan-irrelevant reactive portions remains unclear. Further studies will be needed to elucidate the entire physiological significance of the 1CF11 epitope.
